Site Overlay


The results of the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER; number. Editorial from The New England Journal of Medicine — JUPITER Clinical Directions — Polling Results. Authors & Reviewers · Submit a Manuscript · Subscribers · Institutions · Media · Advertisers · Agents · Permissions · Reprints · NEJM Career.

Author: Yogar Mirg
Country: Spain
Language: English (Spanish)
Genre: Photos
Published (Last): 24 September 2005
Pages: 159
PDF File Size: 2.78 Mb
ePub File Size: 3.50 Mb
ISBN: 680-2-34221-121-9
Downloads: 61607
Price: Free* [*Free Regsitration Required]
Uploader: Vitaxe

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

An I ntervention T rial E valuating R osuvastatin trial was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people jupitr normal cholesterol levels.

JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease. The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP.

Because half of all vascular events occur in patients with normal or low levels nenm LDL cholesterol, JUPITER was designed to determine whether hs-CRP testing could identify these patients, and whether statin therapy could prevent cardiovascular events among them. The trial analyzed 17, patients without evidence of heart disease but with high CRP levels.


JUPITER trial – Wikipedia

Inresults presented at the American Heart Association meeting and published in the New England Journal of Medicine found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had bejm lower rate of major cardiovascular events. Compared to patients taking a placebopatients given rosuvastatin had reductions in LDL and CRP levels, and a reduction of 0.

The trial was stopped early, after just 1. The trial was sponsored by AstraZenecathe marketer of Crestor rosuvastatin. There were no significant differences between the treatment groups with respect to muscle mejm, muscle weakness, hepatic function, or renal function; however, the researchers noted small but statistically significant increases in the rate of physician-reported diabetes and glycated hemoglobin kupiter in the rosuvastatin group, an effect that has also been seen in studies with other statins.

Michel de Lorgeril, et al. The article’s authors critiqued what they saw as flaws in the trial, pointing out that the cardiovascular mortality rate and the case-fatality rate for myocardial infarction were much lower than they expected.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

They also raised concerns about conflict of interest in the trial design and leadership: They concluded that, “The results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors. On juipter role of C-reactive protein, a study employing Mendelian randomizationbejm in the Journal of the American Medical Association suggested that CRP does not play a causal role in cardiovascular disease; the results may argue against CRP’s use as a marker of cardiovascular disease risk or for identifying subjects for statin therapy as in JUPITER, and more strongly argue against using CRP as a therapeutic target per se.


From Wikipedia, the free encyclopedia. Results, Controversies, and Implications nnejm Prevention”.

Cardiovascular Quality and Outcomes. Cleve Clin J Med. Retrieved July 1, Retrieved from ” https: Juputer trials related to cardiology Clinical trials sponsored by AstraZeneca Statins. Views Read Edit View history. This page was last edited on 4 Novemberat By using this site, you agree to the Terms of Use and Privacy Policy.